Sustained virological response in HCV patients treated with daclatasvir plus sofosbuvir, with or without ribavirin: a multicenter, field-practice experience

被引：0

作者：

Sacco, R. ^{[1
]}

Salomoni, E. ^{[2
]}

Parodi, S. ^{[1
]}

Gianni, E. ^{[3
]}

Gragnani, L. ^{[3
]}

Andreotti, G. ^{[4
]}

Brunetto, M. R. ^{[5
]}

Zignego, A. L. ^{[3
]}

Gattai, R. ^{[5
]}

Vivaldi, I. ^{[6
]}

De Luca, A. ^{[7
]}

Bartolozzi, D. ^{[2
]}

Cinelli, R. ^{[6
]}

Pozzi, M. ^{[2
]}

Coco, B. ^{[5
]}

Tapete, G. ^{[1
]}

Forte, P. ^{[8
]}

Puntili, R. ^{[8
]}

Ricciardi, L. ^{[9
]}

Sani, S. ^{[6
]}

Luchi, S. ^{[9
]}

Valoriani, B. ^{[7
]}

Riccardi, M. P. ^{[4
]}

Nencioni, C. ^{[4
]}

Aquilini, D. ^{[10
]}

Nerli, A. ^{[10
]}

Esperti, F. ^{[11
]}

Mazzotta, F. ^{[11
]}

Bresci, G. ^{[1
]}

Colombatto, P. ^{[5
]}

机构：

[1] Azienda Osped Univ Pisana, UO Gastroenterol & Malattie Ricambio, Pisa, Italy

[2] AOU Careggi, Malattie Infett & Trop, Florence, Italy

[3] AOU Careggi, Ctr MASVE Med Sperimentale & Clin, Florence, Italy

[4] Osped Misericordia, Malattie Infett, Grosseto, Italy

[5] Azienda Osped Univ Pisana, UO Epatol, Pisa, Italy

[6] Spedali Riuniti Livorno, Malattie Infett, Livorno, Italy

[7] Azienda Osped Univ Senese, Malattie Infett, Siena, Italy

[8] AOU Careggi, Gastroenterol 2, Florence, Italy

[9] Osped San Luca, Malattie Infett & Epatol, Lucca, Italy

[10] Nuovo Osped Prato, Malattie Infett, Prato, Italy

[11] Osped S Jacopo, Malattie Infett, Pistoia, Italy

来源：

JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期

关键词：

D O I：

10.1016/S0168-8278(17)31958-X

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

SAT-264

引用

页码：S734 / S734

页数：1

共 50 条

[1] SUSTAINED VIROLOGICAL RESPONSE IN HCV PATIENTS TREATED WITH DACLATASVIR plus SOFOSBUVIR, WITH OR WITHOUT RIBAVIRIN: A MULTICENTER, FIELD-PRACTICE EXPERIENCE
Sacco, Rodolfo
Salomoni, Elena
Parodi, Sara
Gianni, Elena
Gragnani, Laura
Andreotti, Giovanni
Zignego, Anna Linda
Gattai, Riccardo
Vivaldi, Ilo
De Luca, Andrea
Bartolozzi, Dario
Cinelli, Roberta
Pozzi, Marco
Coco, Barbara
Tapete, Gherardo
Forte, Paolo
Puntili, Rachele
Ricciardi, Liana
Sani, Spartaco
Luchi, Sauro
Brunetto, Maurizia Rossana
Valoriani, Beatrice
Riccardi, Maria Piera
Nencioni, Cesira
Aquilini, Donatella
Nerli, Alessandro
Esperti, Francesco
Mazzotta, Francesco
Fabiani, Silvia
Menichetti, Francesco
Bresci, Giampaolo
Colombatto, Piero
GASTROENTEROLOGY, 2017, 152 (05) : S1097 - S1097
[2] SUSTAINED VIROLOGICAL RESPONSE IN HCV INFECTED DECOMPENSATED CIRRHOTIC PATIENTS TREATED WITH DACLATASVIR AND SOFOSBUVIR
Tun, Kyaw Thet
Win, Nang K. T.
Kyaw, A. Mi Mi
Lin, Sithu
Maung, Moe Zaw
Myint, Khin Thuzar
Hlaing, Naomi Khaing Than
HEPATOLOGY, 2019, 70 : 967A - 967A
[3] Comparison of Sustained Viral Response with Sofosbuvir Plus Ribavirin and Sofosbuvir Plus Daclatasvir
Idrees, Hifza
Bin Saeed, Saud
Haider, Hammad
PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2018, 12 (03): : 1120 - 1122
[4] Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort
Welzel, Tania M.
Petersen, Joerg
Herzer, Kerstin
Ferenci, Peter
Gschwantler, Michael
Wedemeyer, Heiner
Berg, Thomas
Spengler, Ulrich
Weiland, Ola
van der Valk, Marc
Rockstroh, Juergen
Peck-Radosavljevic, Markus
Zhao, Yue
Jimenez-Exposito, Maria Jesus
Zeuzem, Stefan
GUT, 2016, 65 (11) : 1861 - 1870
[5] Daclatasvir plus sofosbuvir with or without ribavirin in patients with chronic HCV infection: interim analysis of a multicenter compassionate use program
Welzel, T.
Cornberg, M.
Petersen, J.
Herzer, K.
Berg, T.
Spengler, U.
Rockstroh, J.
Ingiliz, P.
Wiegand, J.
Jimenez-Exposito, M.
Zeuzem, S.
JOURNAL OF VIRAL HEPATITIS, 2014, 21 : 24 - 25
[6] Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis
Wahid, Braira
JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (12) : 2195 - 2197
[7] Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir plus interferon plus ribavirin and sofosbuvir plus daclatasvir plus ribavirin)
Wahid, Braira
Shami, Khadija
Joiya, Salman A.
Ozuyar, Sevilay E. G.
Idrees, Muhammad
JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (12) : 3868 - 3870
[8] An integrated safety analysis of daclatasvir plus sofosbuvir, with or without ribavirin, in patients with chronic HCV infection
Landis, Charles S.
Nelson, David R.
Sulkowski, Mark S.
Ruane, Peter J.
Mills, Anthony M.
Poordad, Fred
Wyles, David L.
Bhore, Rafia
Ackerman, Peter
Rana, Khurram
Swenson, Eugene S.
Noviello, Stephanie
HEPATOLOGY, 2015, 62 : 565A - 565A
[9] On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir
Kowdley, Kris V.
Nelson, David R.
Lalezari, Jacob P.
Box, Terry
Gitlin, Norman
Poleynard, Gary
Rabinovitz, Mordechai
Ravendhran, Natarajan
Sheikh, Aasim M.
Siddique, Asma
Bhore, Rafia
Noviello, Stephanie
Rana, Khurram
LIVER INTERNATIONAL, 2016, 36 (11) : 1611 - 1618
[10] Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience
G. Shiha
R. Soliman
M. ElBasiony
A. A. Hassan
N. N. H. Mikhail
Hepatology International, 2018, 12 : 339 - 347

← 1 2 3 4 5 →